Search News Archives
Follow us on
Conferences | Events

Media Partners

 

New Case Study | Gene Editing - Applications and Ethics

publication date: Nov 13, 2018
 | 
author/source: Kolabtree

DNA puzzle


The words of Nobel laureate Sydney Brenner, “Progress in science depends on new techniques, new discoveries and new ideas, probably in that order”, could not be more true for gene editing.

Here, Maya Raghunandan, freelancer for online platform for freelance scientists Kolabtree and molecular biologist, explains some key applications of gene editing and its ethical implications.

Gene editing applications span various industries, most notably food and healthcare. It refers to specific, intentional alterations to the DNA sequence of a cell, tissue or organism to effect a desired change. The alterations range from a simple base pair insertion to large deletions. Gene editing relies on DNA-cutting enzymes called nucleases and the cells’ own DNA repair machinery.

The three main gene editing techniques involve zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered regularly inter-spaced short palindromic repeats (CRISPR), along with Cas9 protein. The advent of the CRISPR-CAS9 technology in 2012 made gene editing much less cumbersome and more user friendly.


Gene editing applications: crops and livestock

The world is already facing a scarcity in food supply, which can only be expected to get worse with the changing climate and uncertain water supplies. Therefore, it is important to generate crops that are more resistant to droughts, cold temperature, pests and other infectious agents. However, while doing so, we must ensure we do not create a highly invasive species of crop that may have detrimental impact on the environment.

Livestock should also be an area of focus due to the population’s high meat consumption, A primary objective while modifying livestock genes is to increase the amount of lean muscle, to make them more valuable for consumption. Gene editing is advantageous over conventional breeding strategies because it’s possible to change the genome of an entire generation in a single go.


Gene editing applications: clinical therapies

Gene therapy holds the promise to correct several genetic disorders including sickle cell anemia, Huntington’s disease and muscular dystrophy. While most gene editing strategies in a clinical setting use an ex-vivo approach, some diseases may not be amenable to these practices. In such cases, in vivo delivery of gene editing tools must be used.

In very special cases, where prospective parents have an elevated risk of having offspring with debilitating genetic disorders, we may need to consider germline editing, which means editing the DNA in gametes. This will allow us to eliminate the diseased gene completely from the lineage and prevent transmission to future generations. As of 2017, we are now capable of genetically editing human embryos. But just because we can, does it mean we should?


Ethical debate

How do we decide which cases warrant germline or embryo editing? Who draws the line for ex vivo versus in vivo therapy? One may argue that gene editing should be allowed for devastating genetic ailments, like Huntington’s disease. But what about people with less life-threatening disabilities, such as dwarfism or hereditary blindness or deafness?

There is also a strong ethical debate about modifying non-pathological human traits for cosmetic purposes. One can envision a scenario in which having a less “appealing” physical feature may cause mental distress and warrant a cosmetic enhancement.

So, to edit or to not edit genomes? While we have achieved the technical ability to edit genomes, scientists still need to discuss and address not just the ethics of editing, but also the safety of the organism and the potential impact on the environment. Regulatory bodies must specify which genetic diseases warrant gene editing and who gets access to this technology. Would it be only for the rich, who can afford it; or for the poor populations and tribes, where a devastating genetic disease may be more prevalent?

From a technology point of view, we are on an unprecedented path of discovery and invention for improving gene editing. The only thing stopping us now is our imagination. Soon, we will be armed with a minimal to no side-effect technology for gene editing. Hence, now is the time to start talking about the ethical burden on this groundbreaking road to a better and healthier world.


more about kolabtree




 

Popular this Month

 

Chromatography in Cannabis Testing

 

New Catalogue of Infectious Disease Antibodies and Antigens

 

Acquisition of B&W Tek takes Metrohm’s Spectroscopy Portfolio to the Next Level

 

Gilson announce the release of the extended mass range VERITY® 1910 MS Detector

 

NanoFCM Opens European Office and Centre of Excellence for Scientific Application Support

 

Hitachi High-Technologies Launches Two New Scanning Electron Microscopes

 

Discovery Park & MedCity to Partner on Prestigious Angels In MedCity Programme

 

Merck Lectureship 2019 Awarded to Susumu Kitagawa

 

BioCity Invests in Carbon Recycling Start-Up, Deep Branch Biotechnology

 

Agilent Announces Unique Portfolio to Advance Immunotherapy

 

 


 

 


 

Can't find what you are looking for?

Search by company or by product


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd